Classification of antiarrythmic drug’s
I'll look up the medical library skill first, then retrieve comprehensive information on antiarrhythmic drug classification.
Reading File
Now let me search for antiarrhythmic drug classification in the textbook library in parallel:
Finding Sources
Finding Sources
Excellent results. Now let me read the best sources in parallel - Katzung (pharmacology), Lippincott (clear classification), and Goodman & Gilman (detailed):
Reading File
Reading File
Reading File
I have excellent content from Lippincott. Let me now read more of that block for the full table and also grab the Katzung antiarrhythmic section and the Harrison's section:
Reading File
Reading File
Reading File
I now have comprehensive content from multiple authoritative textbooks. Let me also fetch the classification diagram from Lippincott:
Finding Sources
Reading File
I now have all the information needed for a thorough, well-cited answer. Let me compile the complete classification:
Classification of Antiarrhythmic Drugs
The standard system is the Vaughan-Williams (Singh-Vaughan Williams) classification, which groups drugs by their predominant effect on the cardiac action potential. It has four classes, with Class I subdivided into three subclasses.
Note: Many antiarrhythmic drugs have actions spanning more than one class. The classification is a useful shorthand but does not fully capture the complexity of drug action. - Katzung's Basic and Clinical Pharmacology, 16th Ed.
Class I - Sodium (Na⁺) Channel Blockers
These drugs block voltage-sensitive Na⁺ channels and show use-dependence (state-dependence): they bind more avidly to open or inactivated channels, so they selectively suppress abnormally rapidly firing cells without affecting normal cardiac rhythm. - Lippincott Illustrated Reviews: Pharmacology
They are subdivided by their kinetics of dissociation from the Na⁺ channel and their effect on action potential duration (APD):
Class IA - Intermediate dissociation kinetics | APD prolonged
| Feature | Detail |
|---|---|
| Mechanism | Block Na⁺ channels (phase 0) + also block K⁺ channels → slow conduction AND prolong repolarization |
| Effect on AP | Slows phase 0 upstroke; also prolongs phase 3 repolarization (widens QRS + prolongs QT) |
| Drugs | Quinidine, Procainamide, Disopyramide |
| Uses | Atrial fibrillation/flutter, SVT, ventricular tachyarrhythmias |
| Key ADRs | QT prolongation, torsades de pointes, proarrhythmia |
Drug-specific toxicities:
- Quinidine: Cinchonism (tinnitus, headache, visual disturbances), hemolytic anemia, esophagitis, anticholinergic effects
- Procainamide: Drug-induced lupus syndrome (anti-histone antibodies), hypotension
- Disopyramide: Marked anticholinergic effects (urinary retention, constipation), strong negative inotropic effect - Lippincott Illustrated Reviews: Pharmacology
Class IB - Rapid dissociation kinetics | APD shortened or unchanged
| Feature | Detail |
|---|---|
| Mechanism | Block Na⁺ channels; rapidly dissociate from resting channels → preferentially act in ischemic/depolarized tissue |
| Effect on AP | Shortens phase 3 repolarization (shortens APD and QT interval) |
| Drugs | Lidocaine, Mexiletine |
| Uses | Ventricular arrhythmias (lidocaine IV for acute/refractory VT/VF); mexiletine orally for chronic ventricular arrhythmias |
| Key ADRs | CNS effects: nystagmus (early toxicity sign), drowsiness, slurred speech, paresthesia, seizures |
- Lidocaine: IV only (extensive first-pass metabolism); metabolized by CYP1A2/CYP3A4
- Mexiletine: Oral; narrow therapeutic index; GI side effects (nausea, vomiting, dyspepsia) - Lippincott Illustrated Reviews: Pharmacology
Class IC - Slow dissociation kinetics | No effect on APD
| Feature | Detail |
|---|---|
| Mechanism | Potent Na⁺ channel blockade; slowly dissociate → marked slowing of conduction in all cardiac tissue |
| Effect on AP | Markedly slows phase 0 upstroke; prominent QRS widening with little change to APD |
| Drugs | Flecainide, Propafenone |
| Uses | Atrial fibrillation/flutter and SVT in patients WITHOUT structural heart disease |
| Key ADRs | Strongly proarrhythmic; can promote reentrant VT (CAST trial: increased mortality post-MI); negative inotropy |
| Contraindication | Structural heart disease (LV dysfunction, CAD, heart failure) - Harrison's Principles of Internal Medicine 22E; Lippincott Illustrated Reviews: Pharmacology |
- Propafenone: Also has mild β-blocking activity; can cause bronchospasm, agranulocytosis
Class II - β-Adrenergic Blockers
| Feature | Detail |
|---|---|
| Mechanism | Inhibit catecholamine-mediated stimulation; suppress phase 4 spontaneous depolarization in SA and AV nodes |
| Effect on AP | Decreased automaticity, slowed AV conduction (↑ PR interval), reduced heart rate |
| Drugs | Atenolol, Esmolol (IV, ultra-short acting), Metoprolol, Propranolol, Bisoprolol |
| Uses | Rate control in AF/AFL; SVT; post-MI ventricular arrhythmias; thyrotoxic arrhythmias |
| Key ADRs | Bradycardia, heart block, hypotension, bronchospasm, fatigue, worsening heart failure |
- Lippincott Illustrated Reviews: Pharmacology; Katzung's Basic and Clinical Pharmacology
Class III - Potassium (K⁺) Channel Blockers
| Feature | Detail |
|---|---|
| Mechanism | Block delayed rectifier K⁺ current (IKr) → prolong phase 3 repolarization → widen APD and refractory period |
| Effect on AP | Prolongs QT interval; increases effective refractory period (ERP) without slowing conduction velocity |
| Drugs | Amiodarone*, Sotalol*, Dofetilide, Ibutilide, Dronedarone* |
* These drugs have multiple class actions
Individual drug profiles:
| Drug | Route | Special Features | Key ADRs |
|---|---|---|---|
| Amiodarone | PO/IV | Has Class I+II+III+IV actions; drug of choice for VT/VF | Pulmonary toxicity (pneumonitis/fibrosis), hepatotoxicity, thyroid dysfunction (hypo- AND hyperthyroid), corneal deposits, blue-gray skin discoloration, peripheral neuropathy, optic neuritis |
| Sotalol | PO | Also a non-selective β-blocker (Class II) | QT prolongation, torsades de pointes, bradycardia |
| Dofetilide | PO | Pure IKr blocker; used in AF/AFL | QT prolongation; must be initiated in hospital |
| Ibutilide | IV only | Used for acute cardioversion of AF/AFL | QT prolongation; torsades de pointes |
| Dronedarone | PO | Amiodarone analog without iodine; mild effects across all classes | Contraindicated in severe HF; hepatotoxicity |
- Lippincott Illustrated Reviews: Pharmacology; Harrison's Principles of Internal Medicine 22E; Katzung's 16th Ed.
Class IV - Calcium (Ca²⁺) Channel Blockers (Non-dihydropyridine)
| Feature | Detail |
|---|---|
| Mechanism | Block L-type Ca²⁺ channels in SA and AV nodes (where AP upstroke is Ca²⁺-dependent) |
| Effect on AP | Slowed AV conduction, decreased automaticity of SA/AV nodes |
| Drugs | Verapamil, Diltiazem |
| Uses | Rate control in AF/AFL; termination of AVNRT (paroxysmal SVT) |
| Key ADRs | Bradycardia, heart block, acute heart failure (especially verapamil), hypotension, constipation |
| Contraindication | Ventricular tachycardia (can cause CV collapse); Wolff-Parkinson-White syndrome with AF |
- Lippincott Illustrated Reviews: Pharmacology
Other/Unclassified Antiarrhythmic Agents
These drugs do not fit neatly into the Vaughan-Williams scheme:
| Drug | Mechanism | Uses | Notes |
|---|---|---|---|
| Adenosine | Activates adenosine A₁ receptors → hyperpolarizes AV node cells | Drug of choice for acute termination of AVNRT/SVT | Ultra-short half-life (~10 sec); causes transient AV block; flushing, dyspnea, chest discomfort |
| Digoxin | Inhibits Na⁺/K⁺-ATPase; increases vagal tone → slows AV conduction | Rate control in AF | Narrow therapeutic index; digitalis toxicity |
| Magnesium | Mechanism not fully clear | Torsades de pointes; digoxin toxicity arrhythmias | First-line for torsades de pointes |
| Atropine | Muscarinic (M₂) antagonist | Symptomatic bradycardia | Blocks vagal tone on SA/AV node |
- Katzung's Basic and Clinical Pharmacology 16th Ed.; Goodman & Gilman's The Pharmacological Basis of Therapeutics
Summary: Effect on Action Potential Phases
| Class | Target | Phase Affected | ECG Change |
|---|---|---|---|
| IA | Na⁺ channel (moderate block) + K⁺ channel | Slows phase 0; prolongs phase 3 | ↑ QRS width + ↑ QT |
| IB | Na⁺ channel (weak, rapid) | Shortens phase 3 | ↓ QT (minimal QRS change) |
| IC | Na⁺ channel (strong, slow) | Markedly slows phase 0 | ↑↑ QRS width |
| II | β-receptor (sympatholytic) | Suppresses phase 4 | ↓ HR, ↑ PR interval |
| III | K⁺ channel | Prolongs phase 3 | ↑↑ QT interval |
| IV | Ca²⁺ channel | Slows phase 0 of nodal tissue | ↓ HR, ↑ PR interval |
Sicilian Gambit (Alternative Classification)
A newer classification - the Sicilian Gambit - classifies antiarrhythmic drugs based on their specific channel and receptor targets (Na⁺, K⁺, Ca²⁺ channels, α- and β-receptors, and other targets) rather than grouping them into broad classes. It is more mechanistically precise but less commonly used clinically than the Vaughan-Williams system. - Textbook of Family Medicine 9e
Key clinical caveat: Amiodarone is unique in sharing Class I, II, III, and IV actions simultaneously. Despite being classified as Class III, it is the broadest-spectrum antiarrhythmic available, and is the drug of choice for hemodynamically unstable VT/VF. However, its long-term toxicity profile (pulmonary, thyroid, hepatic, ocular) demands careful monitoring. - Harrison's Principles of Internal Medicine 22E; Katzung's Basic and Clinical Pharmacology 16th Ed.
This is a shared conversation. Sign in to Orris to start your own chat.